CRISPR Therapeutics (CRSP 3.15%) could revolutionize the healthcare sector, and that has made CRISPR stock a hot buy. While the company isn't profitable yet, it had its first treatment (for sickle cell disease) approved by regulators in December 2023.
It also has promising treatments in the works for cancer and cardiovascular disease, all utilizing the CRISPR gene editing platform. If you're thinking about investing in CRISPR stock, here's how to do it and what you should know first.
How to buy
How to buy CRISPR stock
It's easy to invest in CRISPR Therapeutics since it's a publicly traded company. Follow the steps below to buy CRISPR stock.
- Open your brokerage account: Log in to your brokerage account where you handle your investments.
- Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
- Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
- Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
- Submit your order: Confirm the details and submit your buy order.
- Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.
Stock Ticker
Should I invest?
Should I invest in CRISPR stock?
With CRISPR Therapeutics, it's all about potential. By investing in it, you could get in early with a company that could explode in value, depending on how its product development goes.
Along with partner Vertex Pharmaceuticals (VRTX 2.47%), CRISPR Therapeutics submitted its first treatment, Casgevy (exa-cel), for approval by regulators in 2023. The U.S. Food and Drug Administration approved Casgevy for treatment of sickle cell disease in December 2023 and for treatment of beta-thalassemia in January 2024. And as of June 30, 2025, the company announced that more than 75 authorized treatment centers had been activated globally.
CRISPR Therapeutics receives 40% of profits on Casgevy. The treatment brought in $44.6 million in revenue in the first half of 2025.
The advancement of Casgevy is good news for investors. CRISPR Therapeutics also has other treatments it's developing. It has several cancer therapies in the early-to-mid stages, and it has three clinical-stage programs that would use gene editing to treat cardiovascular disease.
It's important not to be overly optimistic. Biotech is one of the riskiest market sectors, so this is a stock for more aggressive investors. That being said, there's a lot to like about CRISPR stock as an investment. Just remember to be patient and plan to hold it for at least five years.
Buy-and-Hold Strategy
Profitability
Is CRISPR Therapeutics profitable?
CRISPR Therapeutics isn't profitable. It reported a net loss of $362.7 million in 2024. The company also states in its annual report that it has incurred significant operating losses since its inception and expects to do so for the foreseeable future.
This is normal for biotech companies, which are generally unprofitable for long periods of time while developing treatments. It's one of the main reasons they're a higher-risk investment.
Dividends
Does CRISPR Therapeutics pay a dividend?
CRISPR Therapeutics doesn't pay a dividend and is unlikely to in the foreseeable future. Biotech stocks rarely pay dividends, since it makes more sense for them to reinvest profits in developing new treatments. People interested in dividend investing don't have many options in this space.
ETF options
ETFs with exposure to CRISPR Therapeutics
There are quite a few exchange-traded funds (ETFs) that invest in CRISPR Therapeutics. The advantage of investing in ETFs is that they contain a large number of stocks, so you get a much more diversified portfolio than by picking individual stocks. You also save time since you can invest in just one or a few ETFs, which requires less research than picking 25 or more stocks.
Here are a few of the larger ETFs with exposure to CRISPR Therapeutics.
- The Ark Genomic Revolution ETF (ARKG 1.34%) is an actively managed ETF that invests in companies incorporating genomics, including gene editing and gene therapy.
- The Global X Genomics & Biotechnology ETF (GNOM 1.37%) invests in companies that stand to benefit from the advancement of genomic science.
- The ARK Innovation ETF (ARKK 3.69%) is an actively managed fund that invests primarily in companies that fit the fund's theme of disruptive innovation.
These three ETFs all have a fairly high percentage of fund allocation in CRISPR Therapeutics stock. There are also much broader funds containing far more stocks and a smaller CRISPR stock allocation, such as small-cap and mid-cap ETFs.
Stock splits
Will CRISPR Therapeutics stock split?
There's no indication that CRISPR Therapeutics will split its stock. It hasn't had a stock split before, and the option hasn't been discussed publicly. Upcoming stock splits are usually announced at least a few weeks before they happen, and often much earlier, so CRISPR Therapeutics investors will know in advance if it plans to split its stock.
Related investing topics
The bottom line
The bottom line on CRISPR Therapeutics
Gene editing is looking like a major innovation for the healthcare industry, and CRISPR Therapeutics is at the forefront. All of its product candidates use the CRISPR gene-editing technique. With one approved product so far and more hopefully on the way, the sky's the limit.
There are a couple of things to keep in mind if you want to invest in CRISPR stock. The risk and reward are both higher with biotech companies than with most market sectors. You also shouldn't expect immediate results with CRISPR Therapeutics, since most of its treatments are still in the early stages. This is a stock for patient investors who are comfortable with volatility.
FAQs
Investing in CRISPR Therapeutics FAQs
What is the future price of CRISPR stock?
Recent analysis has estimated that CRISPR Therapeutics' share prices could reach around $80 in the near future. However, that's only based on analyst estimates, and it's impossible to predict future stock prices.
Does Bill Gates invest in CRISPR?
Yes, Bill Gates invests in CRISPR technology. The Bill & Melinda Gates Foundation committed a grant of $3.07 million to CRISPR Therapeutics in 2020. Gates was also part of a $120 million funding round in 2015 for Editas (NASDAQ:EDIT), another biotech company that uses CRISPR technology.
Who is the largest shareholder of CRISPR?
ARK Investment Management was the largest shareholder of CRISPR Therapeutics as of Sept. 17, 2025. It holds more than 11% of the company's outstanding shares.
